Form 4: Ocular Therapeutix Director Adrienne L. Graves Reports Stock and Option Grants

Director Adrienne L. Graves received stock and option grants from Ocular Therapeutix, Inc. on July 24, 2024.

Summary

• On July 24, 2024, Adrienne L. Graves, a director of Ocular Therapeutix, Inc., was granted 12,000 restricted stock units (RSUs) and options to purchase 36,000 shares of common stock.
• The RSUs and options were granted under the company's 2021 Stock Incentive Plan, as amended.
• The RSUs represent the right to receive one share of Ocular Therapeutix common stock each.
• Both the RSUs and options vest 100% on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders.
• The exercise price for the stock options is $7.91.
• The options expire on July 23, 2034.
• Following the transaction, Ms. Graves beneficially owns 36,000 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The grant of stock options and RSUs is a standard practice and aligns the director's interests with those of the shareholders. There are no immediate negative implications.

Positives

• The grant of RSUs and stock options aligns the director's interests with those of the shareholders.
• Vesting is tied to continued service on the board, incentivizing long-term commitment.

Future Outlook

The RSUs and options vest on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders, indicating a forward-looking incentive structure.

Industry Context

Stock and option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in the biotech industry, similar to companies like Alnylam Pharmaceuticals and Vertex Pharmaceuticals, where equity-based compensation is used to attract and retain talent.
• The vesting schedule of one year is also typical, aligning with industry norms for incentivizing long-term performance.

Stakeholder Impact

• The grant of RSUs and stock options could have a slightly dilutive effect on existing shareholders.
• The grants incentivize the director to work towards increasing shareholder value.

Key Dates